Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.PH)

ARWR.PH on Philadelphia Stock Exchange

1.60USD
24 May 2017
Change (% chg)

$-0.04 (-2.15%)
Prev Close
$1.63
Open
$1.58
Day's High
$1.62
Day's Low
$1.58
Volume
1,758
Avg. Vol
4,038
52-wk High
$8.21
52-wk Low
$1.21

ARWR.PH

Chart for ARWR.PH

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $119.64
Shares Outstanding(Mil.): 74.77
Dividend: --
Yield (%): --

Financials

  ARWR.PH Industry Sector
P/E (TTM): -- 141.11 17.36
EPS (TTM): -0.92 -- --
ROI: -66.05 2.25 -5.72
ROE: -71.00 0.17 -5.10

BRIEF-Arrowhead reports Q2 revenue $9 million

* Q2 revenue $9 million versus $43,750 Source text for Eikon: Further company coverage:

May 03 2017

BRIEF-Arrowhead Pharmaceuticals adopts stockholder rights agreement

* Arrowhead Pharmaceuticals adopts stockholder rights agreement

Mar 23 2017

BRIEF-Arrowhead reports qtrly loss per share $0.17

* Qtrly loss per share (basic and diluted) $0.17 Source text for Eikon: Further company coverage:

Feb 06 2017

BRIEF-Silence Therapeutics Plc reports 9.21 percent stake in Arrowhead Pharmaceuticals Inc as of Jan 3 - SEC filing

* Silence Therapeutics Plc reports 9.21 percent stake in Arrowhead Pharmaceuticals Inc as of Jan 3 - SEC filing

Jan 13 2017

BRIEF-Arrowhead provides response to new minority shareholder announcement

* Arrowhead provides response to new minority shareholder announcement

Jan 09 2017

Arrowhead Pharma sinks after shelving three drug programs

Shares of Arrowhead Pharmaceuticals Inc sank more than 60 percent in premarket trading on Wednesday, a day after the company said it would stop developing all drugs being tested on humans due to a setback in its drug-delivery technology.

Nov 30 2016

BRIEF-Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

* Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

Nov 29 2016

More From Around the Web

Earnings vs. Estimates